Core Viewpoint - Guangkang Biotech announced the establishment of a joint venture, Shaoguan Henong, with related parties, which involves an investment of 3 million yuan, with no significant adverse impact on the company's finances or operations [1] Group 1: Joint Venture Details - The board of directors approved the investment proposal on October 23, 2025 [1] - The registered capital of the joint venture is 3 million yuan, with Guangzhou Henong contributing 2.55 million yuan, accounting for 85% [1] - Three related individuals, who are the company's deputy general manager and directors, will each contribute 150,000 yuan, representing 5% each [1] Group 2: Transaction Characteristics - The transaction is classified as a related party transaction but does not constitute a major asset restructuring [1] - The pricing follows the principle of fairness, and the funding comes from the company's own resources [1] - The transaction is stated to have no significant adverse impact on the company's financial and operational status [1]
广康生化：全资子公司拟与关联方300万元共同投资设合资公司